Haematocrit on a Steroid Cycle: When to Worry and What to Do About It

Haematocrit on a steroid cycle is the cardiovascular risk factor that kills people slowly and silently. It produces no symptoms in the early stages, reaches dangerous levels before most users realise anything has changed, and is completely manageable with the right monitoring and the right interventions. No other on-cycle health marker rises as predictably, carries as much direct cardiovascular consequence, or is as consistently ignored by UK bodybuilding communities as haematocrit. This guide covers everything you need to know: the mechanism behind why it rises, what the clinical evidence says about the actual cardiovascular risk, how to distinguish secondary erythrocytosis from polycythaemia vera, what the TRAVERSE trial’s findings actually mean for steroid users, and every practical management option available to you. All cycle support compounds referenced throughout this guide are available from the Intex Pharma shop with same day UK despatch.

What haematocrit measures and why it matters on cycle

Haematocrit is the percentage of whole blood volume occupied by red blood cells. Normal male haematocrit sits between 40 and 50 percent in most UK laboratories, with the NHS and British Society for Haematology using 52 percent as the upper threshold for concern in men. When haematocrit rises, blood becomes more viscous. Viscous blood flows through vessels with greater resistance. The heart works harder to maintain adequate perfusion. The risk of thrombus formation increases in slow-flow regions of the vasculature. These are not theoretical risks. They are mechanistically established and clinically documented consequences of elevated haematocrit at bodybuilding doses of testosterone.

Understanding why testosterone raises haematocrit specifically requires understanding two distinct biological mechanisms that operate simultaneously.

The two mechanisms that drive haematocrit elevation on testosterone

Mechanism one: direct erythropoietin stimulation

Testosterone directly upregulates erythropoietin (EPO) production in the kidneys. EPO is the hormone that signals the bone marrow to produce red blood cells. More EPO means more red blood cells, which means higher haematocrit. Research by Bachman et al. published in the Journal of Clinical Endocrinology and Metabolism specifically identified that testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin, effectively establishing a new red blood cell set point at elevated production rates.

Mechanism two: hepcidin suppression

Hepcidin is a liver-derived hormone that regulates iron absorption and red blood cell turnover. Testosterone suppresses hepcidin, which increases iron bioavailability for haemoglobin synthesis. More iron available means more haemoglobin can be produced per red blood cell, and more red blood cells can be sustained. These two mechanisms, EPO elevation and hepcidin suppression, operate concurrently and reinforce each other. The result is a new erythropoietic set point that produces haematocrit values significantly above the physiological baseline in many users.

Men receiving testosterone therapy have approximately three times the risk of developing erythrocytosis compared to untreated men. The degree of elevation depends on testosterone dose, ester type, injection frequency, cycle duration and individual genetic sensitivity to the erythropoietic stimulus. Some users see minimal change at 500mg per week. Others reach 55 to 57 percent at 400mg per week. This variability is real, clinically significant and impossible to predict without monitoring. Pre-cycle haematocrit baseline testing is therefore not optional. It is the only way to know your starting position and assess how much the cycle has pushed you.

Secondary erythrocytosis versus polycythaemia vera: why the distinction matters

Most UK bodybuilding discussions treat elevated haematocrit as a single problem with a single solution. The clinical picture is more nuanced. Elevated haematocrit in steroid users is classified as secondary erythrocytosis, meaning the red blood cell mass is elevated in response to an external stimulus, in this case exogenous testosterone raising EPO. This is fundamentally different from polycythaemia vera.

Polycythaemia vera is a haematological malignancy caused by a JAK2 gene mutation that drives autonomous, EPO-independent overproduction of red blood cells. Research published in Blood Cancer Journal confirmed that secondary erythrocytosis and polycythaemia vera carry different thrombotic risk profiles and require different management approaches. Polycythaemia vera carries inherently higher risk of thrombosis and disease progression than secondary erythrocytosis of any cause.

Why does this distinction matter for steroid users? Because when you present to a UK GP or haematologist with haematocrit of 54 percent on a steroid cycle, the clinical response should be management of secondary erythrocytosis, not investigation for polycythaemia vera. However, if your haematocrit remains elevated long after the cycle ends, or if you develop symptoms inconsistent with simple erythrocytosis such as itching after hot water, unexplained weight loss, or splenomegaly, a JAK2 mutation test to rule out polycythaemia vera is clinically appropriate. The two conditions can coexist and steroids do not protect against polycythaemia vera developing independently.

What the TRAVERSE trial actually tells us about haematocrit and cardiovascular risk

The TRAVERSE trial is the largest randomised controlled trial ever conducted on testosterone therapy cardiovascular safety. Published in the New England Journal of Medicine in 2023, it enrolled 5,246 men at high risk for major adverse cardiovascular events (MACE), randomised them to testosterone therapy or placebo, and followed them for a median of 33 months. The primary finding was that testosterone therapy was not associated with an increased rate of major adverse cardiovascular events compared to placebo.

Within the trial, haematocrit levels of 54 percent or above were observed in 17.0 percent of men in the testosterone group compared to just 3.3 percent in the placebo group. Despite this substantially higher rate of erythrocytosis, there was no corresponding increase in cardiovascular events in the testosterone group. The Androgen Society’s analysis of TRAVERSE specifically noted that the lack of association between raised haematocrit and cardiovascular risk in this trial was reassuring.

This is an important finding and it deserves to be understood properly, not misapplied. The TRAVERSE trial population was on therapeutic TRT doses of testosterone, not the 500mg to 800mg per week bodybuilding doses that push haematocrit far beyond the levels observed in the trial. The men in TRAVERSE were also medically monitored with haematocrit checks and testosterone withdrawal at 54 percent. The trial does not support the conclusion that unlimited haematocrit elevation is safe at bodybuilding doses. What it does support is that therapeutic dose testosterone therapy in medically monitored patients does not cause a statistically significant increase in major cardiovascular events, even when haematocrit rises above 54 percent in a substantial minority of participants.

The takeaway for UK steroid users is not that haematocrit does not matter. It is that monitored, managed haematocrit elevation on cycle carries a lower absolute cardiovascular risk than the worst-case scenarios sometimes presented, while unmonitored and unmanaged haematocrit elevation at high doses remains a genuine concern.

Haematocrit thresholds: what each level means in practice

The following thresholds reflect the clinical guidelines from the British Society for Haematology, the European Urological Association and the practical experience documented in the steroid user literature. They are practical reference points, not absolute triggers for specific actions in all circumstances. Individual risk factors, baseline values and cycle context all inform how each threshold should be interpreted.

Every management option available to you, ranked by mechanism

Testosterone dose reduction

The most direct intervention. Haematocrit elevation is dose-dependent because EPO stimulation is dose-dependent. Dropping from 600mg to 400mg per week typically reduces the rate of haematocrit increase and allows it to stabilise at a lower level over subsequent weeks. For users who consistently reach above 52 percent on higher doses, dose reduction is the most sustainable long-term approach. It does not require clinical involvement, does not carry the iron depletion risk of phlebotomy, and addresses the root cause rather than the consequence.

Injection frequency adjustment

This is the management tool most UK bodybuilders never consider and it can make a meaningful difference before phlebotomy becomes necessary. Higher testosterone peaks from once-weekly injection produce a larger transient erythropoietic stimulus than twice-weekly dosing at the same total weekly dose. Research published in Clinical Endocrinology documented reversal of polycythaemia induced by intramuscular androgen replacement using a lower-peak delivery method, confirming that how testosterone is delivered, not just how much is used, affects haematocrit. Switching from once to twice weekly at the same total dose flattens the testosterone curve, reduces peak concentrations and produces a measurably lower erythropoietic stimulus. Try this before blood donation.

Blood donation at an NHS centre

A standard 450ml whole blood donation reduces haematocrit by approximately 2 to 3 percentage points within days. NHS eligibility criteria do not include anabolic steroid use as a disqualifying factor. You must meet the standard requirements including weight, iron levels and travel history. The reduction is immediate and real.

There is an important caveat that most bodybuilding resources omit. A Canadian Blood Services case series of 39 TRT patients who donated blood found that repeat blood donation was insufficient to maintain haematocrit below 54 percent in a significant proportion of donors, and the authors raised specific concern that patients were developing a false sense of security that donation had abrogated the cardiovascular risk. Donation helps but is not a complete solution when the underlying testosterone dose continues driving haematocrit upward between donations. It works best combined with dose or frequency adjustment.

Therapeutic phlebotomy at a private clinic

Identical to blood donation in terms of volume removed and haematocrit reduction, but without the eligibility restrictions. Available at several UK private clinics for approximately £50 to £150 per session. The practical advantage is availability regardless of your travel history, recent illness or other donation exclusion criteria. Some clinics in London, Manchester and Birmingham offer this specifically for TRT and performance users.

Ferritin and iron management: the complication most users create for themselves

This is the most overlooked aspect of haematocrit management in the UK bodybuilding community and it is where the most avoidable harm occurs. Every blood donation or therapeutic phlebotomy removes iron-containing red blood cells. If donations are frequent and iron intake is inadequate, ferritin drops. When ferritin drops too low, iron deficiency anaemia can develop despite haematocrit appearing to normalise. The symptoms of iron deficiency anaemia, fatigue, reduced exercise capacity, poor recovery and cognitive impairment, are often attributed to other aspects of the cycle when the cause is actually donation-induced iron depletion.

Always check ferritin before donating. The NHS requires a minimum haemoglobin of 12.5 g/dL for women and 13.5 g/dL for men before accepting a donation, but this threshold does not capture early iron depletion that has not yet depressed haemoglobin. Running a ferritin level alongside your haematocrit check tells you whether your iron stores can sustain a donation. Values below 30 mcg/L suggest iron stores are marginal even if haematocrit remains elevated. Donation at this point risks driving ferritin lower still and creating a secondary problem.

Hydration

Dehydration causes haemoconcentration, a temporary increase in haematocrit from reduced plasma volume rather than increased red blood cell mass. A reading taken while dehydrated can be two to three percentage points higher than the true erythrocytosis-driven value. Ensuring adequate hydration before testing prevents false alarms. Maintaining 3 to 4 litres of fluid per day on cycle prevents dehydration from compounding the genuine haematocrit elevation from erythropoiesis. Hydration alone does not lower haematocrit that has genuinely risen from testosterone-driven red blood cell production, but it prevents the additional viscosity increase from haemoconcentration stacking on top.

Daily Tadalafil for the cardiovascular component

Intex Pharma Cialis at 5mg daily does not lower haematocrit. What it does is address the blood pressure component of the cardiovascular risk picture that elevated haematocrit creates. Thicker blood at higher pressure creates more mechanical stress on vessel walls than thicker blood at lower pressure. Tadalafil reduces peripheral vascular resistance through PDE5 inhibition, lowering the pressure variable while you address the viscosity variable through the haematocrit management strategies above. These are not alternative approaches. They address different components of the same risk and work best deployed together as part of a complete on-cycle cardiovascular support protocol.

When to test haematocrit: the complete monitoring schedule

Always test at rest, well-hydrated and in the morning before training. Exercise causes haemoconcentration from fluid shifts into working muscle, temporarily elevating haematocrit by 2 to 3 percentage points. Testing immediately post-training produces a falsely elevated reading that can trigger unnecessary interventions.

The symptom problem: why you cannot rely on how you feel

Many users with haematocrit in the low 50s are completely asymptomatic. This is the most dangerous aspect of haematocrit elevation, not its severity when symptomatic but its invisibility when building. The cardiovascular damage from chronically elevated blood viscosity accumulates structurally over time — increased left ventricular wall stress, progressive arterial stiffness, elevated thrombotic risk — without producing the kind of noticeable symptoms that prompt action in the moment.

When symptoms do appear they typically include persistent headaches particularly on waking, dizziness on standing, visual disturbances, facial flushing, unusual fatigue disproportionate to training load and a sense of heaviness or pressure in the head. Any combination of these symptoms on cycle is a signal to test haematocrit immediately rather than attribute them to other cycle side effects. Waiting for symptoms before testing is the wrong strategy. The whole point of monitoring is to catch elevation before it becomes symptomatic.

Sleep apnoea: the haematocrit risk factor almost no one mentions

Obstructive sleep apnoea (OSA) independently raises haematocrit through chronic intermittent hypoxia, which stimulates EPO production through the same pathway that testosterone uses. A steroid user who also has undiagnosed OSA, which is substantially more common in muscular, heavier men than in the general population, faces additive erythropoietic stimulation from two concurrent mechanisms. The result is haematocrit elevation that outpaces what the testosterone dose alone would typically produce and that does not respond to dose reduction as expected.

If your haematocrit is rising faster than expected for your dose and cycle duration, or if it fails to fall adequately after dose reduction or donation, OSA is worth investigating. Snoring, witnessed breath-holding during sleep, morning headaches and persistent daytime fatigue are the key OSA symptoms to consider. This is the nuance that most haematocrit guides entirely omit, and it is clinically relevant for a bodybuilding population.

Frequently asked questions

Related guides from Intex Pharma

• Blood pressure on a steroid cycle and the role of Tadalafil
• Bloodwork before your first steroid cycle — the complete UK panel
• How to read your testosterone bloodwork results
• Intex Pharma T400 review — bloodwork results and full analysis
• Best Intex Pharma beginner cycle 2026 — test only, step by step